Austria
· Delayed Price · Currency is EUR Marinomed Biotech AG Company Description
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally.
The company operates through Virology, Immunology, and Other segments. Its products pipeline includes Budesolv for the treatment of allergic rhinitis; Tacrosolv, which is in Phase II clinical trial for inflammatory eye diseases; Carravin for the treatment of nasal congestion; and Inhaleen for viral pneumonia, as well as Carragelose, which consists of nasal and throat sprays, and lozenges for treating viral respiratory infections.
The company has a technology partnership with SPH Sine Pharmaceutical Laboratories Co. Ltd. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017.
Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.
| Country | Austria |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 52 |
| CEO | Andreas Grassauer |
Contact Details
Address: Hovengasse 25 Korneuburg, Vienna 2100 Austria | |
| Phone | 43 2262 90300 |
| Website | marinomed.com |
Stock Details
| Ticker Symbol | MARI |
| Exchange | Vienna Stock Exchange |
| Fiscal Year | April - March |
| Reporting Currency | EUR |
| ISIN Number | ATMARINOMED6 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Andreas Grassauer | Co-Founder, Chairman of Management Board and Chief Executive Officer |
| Eva Prieschl-Grassauer | Co-Founder, Vice Chairwoman of Management Board and Chief Scientific Officer |
| Pascal Schmidt | Chief Financial Officer and Member of Management Board |
| Stephanie Kniep | Head of Investor Relations |
| Dr. Angelika Bodenteich | Head of Development |
| Helmut Baranyovszki | Head of Staff |
| Renate Moser | Head of Business Development |